{"DataElement":{"publicId":"4551296","version":"1","preferredName":"Transplant Conditioning Regimen Agents Type","preferredDefinition":"the type of conditioning regimen agents used to prepare a person for receipt of a transplant.","longName":"XptCndRgmAgtTp","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"2198273","version":"1","preferredName":"Transplant Conditioning Regimen","preferredDefinition":"A treatment plan to prepare a person for receipt of a transplant.","longName":"TSPL_COND_RGM","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2206967","version":"1","preferredName":"Transplant Conditioning","preferredDefinition":"Healthy skin, bone, or other tissue taken from one part of the body and used to replace diseased or injured tissue removed from another part of the body.:Generally refers to relative simple learning situations in which a stimulus initially incapable of evoking a certain response acquires the ability to do so by repeated pairing with another stimulus that does elicit the response.","longName":"C12981:C41258","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Graft","conceptCode":"C12981","definition":"Tissue or organ transplanted from a donor to a recipient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Conditioning","conceptCode":"C41258","definition":"Generally refers to relative simple learning situations in which a stimulus initially incapable of evoking a certain response acquires the ability to do so by repeated pairing with another stimulus that does elicit the response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-1262-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177402","version":"1","preferredName":"Regimen","preferredDefinition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","longName":"Regimen","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-527D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEFD9E97-FD88-0048-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-02-02","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4551291","version":"1","preferredName":"Transplant Conditioning Regimen Agents Type","preferredDefinition":"Description of the type of conditioning regimen agents used to prepare a person for receipt of a transplant.","longName":"XptCndRgmAgtTp","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"ALPHANUMERIC","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"TBI 1200/Etoposide/Cyclophosphamide","valueDescription":"TBI 1200/Etoposide/Cyclophosphamide","ValueMeaning":{"publicId":"4551294","version":"1","preferredName":"TBI 1200/Etoposide/Cyclophosphamide","longName":"4551294","preferredDefinition":"Radiation therapy to the entire body. It is usually followed by bone marrow or peripheral stem cell transplantation.: A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04): A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Total-Body Irradiation","conceptCode":"C15350","definition":"A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"060A635D-B3FD-A075-E050-BB89AD434EF6","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"062DD251-CABF-C2C3-E050-BB89AD431868","beginDate":"2014-10-22","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-24","modifiedBy":"ONEDATA","dateModified":"2014-10-24","deletedIndicator":"No"},{"value":"TBI 1200/Thiotepa/Cyclophosphamide","valueDescription":"TBI 1200/Thiotepa/Cyclophosphamide","ValueMeaning":{"publicId":"4551295","version":"1","preferredName":"TBI 1200/Thiotepa/Cyclophosphamide","longName":"4551295","preferredDefinition":"Radiation therapy to the entire body. It is usually followed by bone marrow or peripheral stem cell transplantation.: A synthetic alkylating agent. Related to nitrogen mustard, thiotepa alkylates and crosslinks DNA, resulting in the inhibition of DNA replication. (NCI04): A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Total-Body Irradiation","conceptCode":"C15350","definition":"A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Thiotepa","conceptCode":"C875","definition":"A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"060A635D-B424-A075-E050-BB89AD434EF6","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"062DD251-CAD3-C2C3-E050-BB89AD431868","beginDate":"2014-10-22","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-24","modifiedBy":"ONEDATA","dateModified":"2014-10-24","deletedIndicator":"No"},{"value":"TBI 1320/Cyclophosphamide","valueDescription":"TBI 1320/Cyclophosphamide","ValueMeaning":{"publicId":"4551293","version":"1","preferredName":"TBI 1320/Cyclophosphamide","longName":"4551293","preferredDefinition":"Radiation therapy to the entire body. It is usually followed by bone marrow or peripheral stem cell transplantation.: A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Total-Body Irradiation","conceptCode":"C15350","definition":"A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"060A635D-B3D6-A075-E050-BB89AD434EF6","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"062DD251-CAE7-C2C3-E050-BB89AD431868","beginDate":"2014-10-22","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-24","modifiedBy":"ONEDATA","dateModified":"2014-10-24","deletedIndicator":"No"},{"value":"TBI 1320/Fludarabine/Cyclophosphamide","valueDescription":"TBI 1320/Fludarabine/Cyclophosphamide","ValueMeaning":{"publicId":"4551292","version":"1","preferredName":"TBI 1320/Fludarabine/Cyclophosphamide","longName":"4551292","preferredDefinition":"Radiation therapy to the entire body. It is usually followed by bone marrow or peripheral stem cell transplantation.: A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04): A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Total-Body Irradiation","conceptCode":"C15350","definition":"A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Fludarabine","conceptCode":"C1094","definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"060A635D-B3B0-A075-E050-BB89AD434EF6","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"062DD251-CAFB-C2C3-E050-BB89AD431868","beginDate":"2014-10-22","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-24","modifiedBy":"ONEDATA","dateModified":"2014-10-24","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"5170771","version":"1","preferredName":"Other","longName":"5170771","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E4D2332-841D-A760-E050-BB89AD43734F","latestVersionIndicator":"Yes","beginDate":"2016-03-18","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"415CA911-0AA1-28BD-E053-F662850AAA2B","beginDate":"2016-11-15","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-15","modifiedBy":"ONEDATA","dateModified":"2016-11-15","deletedIndicator":"No"},{"value":"Thiotepa","valueDescription":"Thiotepa","ValueMeaning":{"publicId":"2739553","version":"1","preferredName":"Thiotepa","longName":"2739553","preferredDefinition":"A synthetic alkylating agent. Related to nitrogen mustard, thiotepa alkylates and crosslinks DNA, resulting in the inhibition of DNA replication. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thiotepa","conceptCode":"C875","definition":"A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-0294-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"415CA911-0AAB-28BD-E053-F662850AAA2B","beginDate":"2016-11-15","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-15","modifiedBy":"ONEDATA","dateModified":"2016-11-15","deletedIndicator":"No"},{"value":"TBI","valueDescription":"TBI","ValueMeaning":{"publicId":"5577160","version":"1","preferredName":"TBI","longName":"5577160v1.00","preferredDefinition":"A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Total-Body Irradiation","conceptCode":"C15350","definition":"A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"415CA911-0AB5-28BD-E053-F662850AAA2B","latestVersionIndicator":"Yes","beginDate":"2016-11-15","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-15","modifiedBy":"KUMMEROA","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"415CA911-0ACE-28BD-E053-F662850AAA2B","beginDate":"2016-11-15","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-15","modifiedBy":"ONEDATA","dateModified":"2016-11-15","deletedIndicator":"No"},{"value":"Fludarabine","valueDescription":"Fludarabine","ValueMeaning":{"publicId":"2568535","version":"1","preferredName":"Fludarabine","longName":"2568535","preferredDefinition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fludarabine","conceptCode":"C1094","definition":"A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8C4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"REEVESD","dateModified":"2005-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"415CA911-0AD8-28BD-E053-F662850AAA2B","beginDate":"2016-11-15","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-15","modifiedBy":"ONEDATA","dateModified":"2016-11-15","deletedIndicator":"No"},{"value":"Cyclophosphamide","valueDescription":"Cyclophosphamide","ValueMeaning":{"publicId":"5127394","version":"1","preferredName":"Cyclophosphamide","longName":"5127394","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-F9F9-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"415CA911-0AE2-28BD-E053-F662850AAA2B","beginDate":"2016-11-15","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-15","modifiedBy":"ONEDATA","dateModified":"2016-11-15","deletedIndicator":"No"},{"value":"Busulfan","valueDescription":"Busulfan","ValueMeaning":{"publicId":"2739539","version":"1","preferredName":"Busulfan","longName":"2739539","preferredDefinition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Busulfan","conceptCode":"C321","definition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BBD0-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"415CA911-0AEC-28BD-E053-F662850AAA2B","beginDate":"2016-11-15","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-15","modifiedBy":"ONEDATA","dateModified":"2016-11-15","deletedIndicator":"No"},{"value":"Melphalan","valueDescription":"Melphalan","ValueMeaning":{"publicId":"2654276","version":"1","preferredName":"Melphalan","longName":"2654276","preferredDefinition":"An orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melphalan","conceptCode":"C633","definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32CD72AB-9FA5-289C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-06-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"41841370-FAEE-1FC0-E053-F662850A041F","beginDate":"2016-11-17","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-11-17","modifiedBy":"ONEDATA","dateModified":"2016-11-17","deletedIndicator":"No"},{"value":"Total Lymphoid Irradiation","valueDescription":"Total Lymphoid Irradiation","ValueMeaning":{"publicId":"5678510","version":"1","preferredName":"Total Lymphoid Irradiation","longName":"5678510","preferredDefinition":"Total Lymphoid Irradiation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497672BA-01B3-78A5-E053-F662850A58ED","latestVersionIndicator":"Yes","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"497672BA-01CC-78A5-E053-F662850A58ED","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"ONEDATA","dateModified":"2017-02-26","deletedIndicator":"No"},{"value":"Etoposide","valueDescription":"Etoposide","ValueMeaning":{"publicId":"2739535","version":"1","preferredName":"Etoposide","longName":"2739535","preferredDefinition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BAFB-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"KUMMEROA","dateModified":"2022-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"497672BA-01D6-78A5-E053-F662850A58ED","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"ONEDATA","dateModified":"2017-02-26","deletedIndicator":"No"},{"value":"Cytosine Arabinoside","valueDescription":"Cytosine Arabinoside","ValueMeaning":{"publicId":"2724325","version":"1","preferredName":"Cytosine Arabinoside","longName":"2724325","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"443FAAF5-4136-370B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALAIS","dateCreated":"2008-01-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"497672BA-01EA-78A5-E053-F662850A58ED","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"ONEDATA","dateModified":"2017-02-26","deletedIndicator":"No"},{"value":"Carboplatin","valueDescription":"Carboplatin","ValueMeaning":{"publicId":"3378841","version":"1","preferredName":"Carboplatin","longName":"3378841","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-17C6-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"497672BA-01F4-78A5-E053-F662850A58ED","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"ONEDATA","dateModified":"2017-02-26","deletedIndicator":"No"},{"value":"Clofararabine","valueDescription":"Clofarabine","ValueMeaning":{"publicId":"3378889","version":"1","preferredName":"Clofarabine","longName":"3378889","preferredDefinition":"A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5'-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clofarabine","conceptCode":"C26638","definition":"A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5'-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-408F-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"74AAC5A2-2DDC-6E8D-E053-F662850AA32B","beginDate":"2018-08-30","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2018-08-30","modifiedBy":"ONEDATA","dateModified":"2018-08-30","deletedIndicator":"No"},{"value":"Clofarabine","valueDescription":"Clofarabine","ValueMeaning":{"publicId":"3378889","version":"1","preferredName":"Clofarabine","longName":"3378889","preferredDefinition":"A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5'-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clofarabine","conceptCode":"C26638","definition":"A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5'-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-408F-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76A05D91-5F71-76E9-E053-F662850A0503","beginDate":"2018-08-30","endDate":null,"createdBy":"SORTILLD","dateCreated":"2018-09-24","modifiedBy":"ONEDATA","dateModified":"2018-09-24","deletedIndicator":"No"},{"value":"Reduced-intensity conditioning/non-myeloablative","valueDescription":"Reduced-intensity conditioning/non-myeloablative","ValueMeaning":{"publicId":"6810464","version":"1","preferredName":"Reduced-intensity conditioning/non-myeloablative","longName":"6810464","preferredDefinition":"A conditioning regimen that uses less chemotherapy and radiation than the standard myeloablative conditioning regimen.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8CA32E54-32D4-680A-E053-F662850A5221","latestVersionIndicator":"Yes","beginDate":"2019-07-01","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-07-01","modifiedBy":"ONEDATA","dateModified":"2019-07-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CA32E54-32ED-680A-E053-F662850A5221","beginDate":"2019-07-01","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-07-01","modifiedBy":"ONEDATA","dateModified":"2019-07-01","deletedIndicator":"No"},{"value":"Other myeloablative conditioning/TBI containing","valueDescription":"Other myeloablative conditioning/TBI containing","ValueMeaning":{"publicId":"6810319","version":"1","preferredName":"Other myeloablative conditioning/TBI containing","longName":"6810319","preferredDefinition":"A other high-dose chemotherapy that kills cells in the bone marrow, including cancer cells and contains total body irradiation therapy.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8CA3097C-618F-67F6-E053-F662850A6221","latestVersionIndicator":"Yes","beginDate":"2019-07-01","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-07-01","modifiedBy":"ONEDATA","dateModified":"2019-07-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CA3097C-61A8-67F6-E053-F662850A6221","beginDate":"2019-07-01","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-07-01","modifiedBy":"ONEDATA","dateModified":"2019-07-01","deletedIndicator":"No"},{"value":"Myeloablative/non-TBI containing","valueDescription":"Myeloablative/non-TBI containing","ValueMeaning":{"publicId":"6810320","version":"1","preferredName":"Myeloablative/non-TBI containing","longName":"6810320","preferredDefinition":"A high-dose chemotherapy that kills cells in the bone marrow, including cancer cells that does not contain total body irradiation therapy.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8CA3228A-23DF-6806-E053-F662850A82CF","latestVersionIndicator":"Yes","beginDate":"2019-07-01","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-07-01","modifiedBy":"ONEDATA","dateModified":"2019-07-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8CA3228A-23F8-6806-E053-F662850A82CF","beginDate":"2019-07-01","endDate":null,"createdBy":"SORTILLD","dateCreated":"2019-07-01","modifiedBy":"ONEDATA","dateModified":"2019-07-01","deletedIndicator":"No"},{"value":"Total Body Irradiation","valueDescription":"Total-Body Irradiation","ValueMeaning":{"publicId":"3228419","version":"1","preferredName":"Total-Body Irradiation","longName":"3228419","preferredDefinition":"Radiation therapy to the entire body. Usually followed by bone marrow or peripheral stem cell transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Total-Body Irradiation","conceptCode":"C15350","definition":"A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A16E86D8-A4DB-A34E-E040-BB89AD434C07","latestVersionIndicator":"Yes","beginDate":"2011-04-21","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-04-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91C3A83E-0206-0C69-E053-F662850A3967","beginDate":"2019-09-04","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-09-04","modifiedBy":"ONEDATA","dateModified":"2019-09-04","deletedIndicator":"No"},{"value":"ATG (Anti-Thymocyte Globulin)","valueDescription":"Anti-Thymocyte Globulin","ValueMeaning":{"publicId":"3253646","version":"1","preferredName":"Anti-Thymocyte Globulin","longName":"3253646","preferredDefinition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-Thymocyte Globulin","conceptCode":"C278","definition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A81EFF99-7AB2-7C87-E040-BB89AD430597","latestVersionIndicator":"Yes","beginDate":"2011-07-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-07-15","modifiedBy":"KUMMEROA","dateModified":"2022-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91BF0B6C-0AF5-2CEC-E053-F662850AC632","beginDate":"2019-09-04","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-09-04","modifiedBy":"ONEDATA","dateModified":"2019-09-04","deletedIndicator":"No"},{"value":"Alemtuzumab","valueDescription":"Alemtuzumab","ValueMeaning":{"publicId":"2577772","version":"1","preferredName":"Alemtuzumab","longName":"2577772","preferredDefinition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alemtuzumab","conceptCode":"C1681","definition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ALEYR","dateModified":"2008-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"91D2B267-F866-0550-E053-F662850AA184","beginDate":"2019-09-05","endDate":null,"createdBy":"PROSVIROVAB","dateCreated":"2019-09-05","modifiedBy":"ONEDATA","dateModified":"2019-09-05","deletedIndicator":"No"},{"value":"Total Body Irradiation/Cyclophosphamide","valueDescription":"Total Body Irradiation/Cyclophosphamide","ValueMeaning":{"publicId":"7117790","version":"1","preferredName":"Total Body Irradiation/Cyclophosphamide","longName":"7117790","preferredDefinition":"Total Body Irradiation/Cyclophosphamide","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AF2FA40-77D3-4FE2-E053-F662850A6ACE","latestVersionIndicator":"Yes","beginDate":"2019-12-30","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-30","modifiedBy":"ONEDATA","dateModified":"2019-12-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9AF2FA40-77EC-4FE2-E053-F662850A6ACE","beginDate":"2019-12-30","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-30","modifiedBy":"ONEDATA","dateModified":"2019-12-30","deletedIndicator":"No"},{"value":"Busulfan/Cyclophosphamide","valueDescription":"Busulfan/Cyclophosphamide","ValueMeaning":{"publicId":"7117791","version":"1","preferredName":"Busulfan/Cyclophosphamide","longName":"7117791","preferredDefinition":"Busulfan/Cyclophosphamide","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AF2FA40-77F6-4FE2-E053-F662850A6ACE","latestVersionIndicator":"Yes","beginDate":"2019-12-30","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-30","modifiedBy":"ONEDATA","dateModified":"2019-12-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9AF2FA40-780F-4FE2-E053-F662850A6ACE","beginDate":"2019-12-30","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-30","modifiedBy":"ONEDATA","dateModified":"2019-12-30","deletedIndicator":"No"},{"value":"Fludarabine/Clofarabine/Busulfan","valueDescription":"Fludarabine/Clofarabine/Busulfan","ValueMeaning":{"publicId":"7117792","version":"1","preferredName":"Fludarabine/Clofarabine/Busulfan","longName":"7117792","preferredDefinition":"Fludarabine/Clofarabine/Busulfan","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AF2FA40-7819-4FE2-E053-F662850A6ACE","latestVersionIndicator":"Yes","beginDate":"2019-12-30","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-30","modifiedBy":"ONEDATA","dateModified":"2019-12-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9AF2FA40-7832-4FE2-E053-F662850A6ACE","beginDate":"2019-12-30","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-30","modifiedBy":"ONEDATA","dateModified":"2019-12-30","deletedIndicator":"No"},{"value":"Fludarabine/Busulfan","valueDescription":"Fludarabine/Busulfan","ValueMeaning":{"publicId":"7117793","version":"1","preferredName":"Fludarabine/Busulfan","longName":"7117793","preferredDefinition":"Fludarabine/Busulfan","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AF2FA40-783C-4FE2-E053-F662850A6ACE","latestVersionIndicator":"Yes","beginDate":"2019-12-30","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-30","modifiedBy":"ONEDATA","dateModified":"2019-12-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9AF2FA40-7855-4FE2-E053-F662850A6ACE","beginDate":"2019-12-30","endDate":null,"createdBy":"LEEW","dateCreated":"2019-12-30","modifiedBy":"ONEDATA","dateModified":"2019-12-30","deletedIndicator":"No"},{"value":"Reduced intensity","valueDescription":"Reduced Intensity","ValueMeaning":{"publicId":"4383037","version":"1","preferredName":"Reduced Intensity","longName":"4383037v1.00","preferredDefinition":"A method of preparation for stem cell transplant that uses less than standard doses of chemotherapy and radiation prior to the transfer of stem cells, with the goal of providing protection against graft vs. host disease, while simultaneously minimizing the toxic effects of the conditioning treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reduced-Intensity Transplant Conditioning Procedure","conceptCode":"C116471","definition":"A method of preparation for stem cell transplant that uses less than standard doses of chemotherapy and radiation prior to the transfer of stem cells, with the goal of providing protection against graft vs. host disease, while simultaneously minimizing the toxic effects of the conditioning treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FDC84AA1-9BFA-FC5A-E040-BB89AD433AD9","latestVersionIndicator":"Yes","beginDate":"2014-07-09","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2014-07-09","modifiedBy":"MMADDINENI","dateModified":"2022-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0F8BF6F-7B30-32FC-E053-4EBD850A140D","beginDate":"2021-04-27","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-27","modifiedBy":"ONEDATA","dateModified":"2021-04-27","deletedIndicator":"No"},{"value":"Chemotherapy based recommended regimen","valueDescription":"Chemotherapy based recommended regimen","ValueMeaning":{"publicId":"8078619","version":"1","preferredName":"Chemotherapy based recommended regimen","longName":"8078619","preferredDefinition":"Chemotherapy based recommended regimen consisting of anti-thymocyte globulin, Fludarabine, Busulfan, Thiotepa and post-transplant Methotrexate.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9E4E186-97CE-1B1A-E053-4EBD850A0174","latestVersionIndicator":"Yes","beginDate":"2022-03-10","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-10","modifiedBy":"ONEDATA","dateModified":"2022-03-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9E4E186-97E9-1B1A-E053-4EBD850A0174","beginDate":"2022-03-10","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-10","modifiedBy":"ONEDATA","dateModified":"2022-03-10","deletedIndicator":"No"},{"value":"TBI based recommended regimen","valueDescription":"TBI based recommended regimen","ValueMeaning":{"publicId":"8078620","version":"1","preferredName":"TBI based recommended regimen","longName":"8078620","preferredDefinition":"Total body irradiation based recommended regimen consisting of Anti-thymocyte globulin, Cyclophosphamise,TBI  and post transplant Methotrexate.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9E4E186-97F3-1B1A-E053-4EBD850A0174","latestVersionIndicator":"Yes","beginDate":"2022-03-10","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-10","modifiedBy":"ONEDATA","dateModified":"2022-03-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9E4E186-980E-1B1A-E053-4EBD850A0174","beginDate":"2022-03-10","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-10","modifiedBy":"ONEDATA","dateModified":"2022-03-10","deletedIndicator":"No"},{"value":"Myeloablative Option 2","valueDescription":"Busulfan/Thiotepa/Fludarabine/ATG","ValueMeaning":{"publicId":"8078621","version":"1","preferredName":"Busulfan/Thiotepa/Fludarabine/ATG","longName":"8078621","preferredDefinition":"Busulfan/Thiotepa/Fludarabine/Anti-thymocyte globulin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9E4E186-9818-1B1A-E053-4EBD850A0174","latestVersionIndicator":"Yes","beginDate":"2022-03-10","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-10","modifiedBy":"ONEDATA","dateModified":"2022-03-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9E4E186-9834-1B1A-E053-4EBD850A0174","beginDate":"2022-03-10","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-10","modifiedBy":"ONEDATA","dateModified":"2022-03-10","deletedIndicator":"No"},{"value":"Myeloablative Option 1","valueDescription":"TBI/Thiotepa/Fludarabine/ATG","ValueMeaning":{"publicId":"8078622","version":"1","preferredName":"TBI/Thiotepa/Fludarabine/ATG","longName":"8078622","preferredDefinition":"Total Body Irradiation/Thiotepa/Fludarabine/Anti-thymocyte globulin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9E4E186-983E-1B1A-E053-4EBD850A0174","latestVersionIndicator":"Yes","beginDate":"2022-03-10","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-10","modifiedBy":"ONEDATA","dateModified":"2022-03-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9E4E186-985A-1B1A-E053-4EBD850A0174","beginDate":"2022-03-10","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-10","modifiedBy":"ONEDATA","dateModified":"2022-03-10","deletedIndicator":"No"},{"value":"Reduced toxicity Option 1","valueDescription":"Alpha Beta T cell depleted Reduced Toxicity Option 1: Fludarabine/Thiotepa/Melphalan/ATG","ValueMeaning":{"publicId":"8078623","version":"1","preferredName":"Alpha Beta T cell depleted Reduced Toxicity Option 1: Fludarabine/Thiotepa/Melphalan/ATG","longName":"8078623","preferredDefinition":"Alpha Beta T cell depleted Reduced Toxicity Option 1: Fludarabine/Thiotepa/Melphalan/ATG","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9E4E186-9864-1B1A-E053-4EBD850A0174","latestVersionIndicator":"Yes","beginDate":"2022-03-10","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-10","modifiedBy":"ONEDATA","dateModified":"2022-03-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9E4E186-9880-1B1A-E053-4EBD850A0174","beginDate":"2022-03-10","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-10","modifiedBy":"ONEDATA","dateModified":"2022-03-10","deletedIndicator":"No"},{"value":"Regimen C","valueDescription":"Reduced toxicity fludarabine/TBI","ValueMeaning":{"publicId":"8078624","version":"1","preferredName":"Reduced toxicity fludarabine/TBI","longName":"8078624","preferredDefinition":"Reduced toxicity fludarabine/Total Body Irradiation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9E4E186-988A-1B1A-E053-4EBD850A0174","latestVersionIndicator":"Yes","beginDate":"2022-03-10","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-10","modifiedBy":"ONEDATA","dateModified":"2022-03-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9E4E186-98A6-1B1A-E053-4EBD850A0174","beginDate":"2022-03-10","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-10","modifiedBy":"ONEDATA","dateModified":"2022-03-10","deletedIndicator":"No"},{"value":"Regimen B","valueDescription":"TBI/Cyclophosphamide/Post-transplant Cyclophosphamide","ValueMeaning":{"publicId":"8078625","version":"1","preferredName":"TBI/Cyclophosphamide/Post-transplant Cyclophosphamide","longName":"8078625","preferredDefinition":"Total Body Irradiation/Cyclophosphamide/Post-transplant Cyclophosphamide","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9E4E186-98B0-1B1A-E053-4EBD850A0174","latestVersionIndicator":"Yes","beginDate":"2022-03-10","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-10","modifiedBy":"ONEDATA","dateModified":"2022-03-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9E4E186-98CC-1B1A-E053-4EBD850A0174","beginDate":"2022-03-10","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-10","modifiedBy":"ONEDATA","dateModified":"2022-03-10","deletedIndicator":"No"},{"value":"Regimen A","valueDescription":"Busulfan/Cyclophosphamide/Post-transplant Cyclophosphamide","ValueMeaning":{"publicId":"8078626","version":"1","preferredName":"Busulfan/Cyclophosphamide/Post-transplant Cyclophosphamide","longName":"8078626","preferredDefinition":"Busulfan/Cyclophosphamide/Post-transplant Cyclophosphamide","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9E4E186-98D6-1B1A-E053-4EBD850A0174","latestVersionIndicator":"Yes","beginDate":"2022-03-10","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-10","modifiedBy":"ONEDATA","dateModified":"2022-03-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9E4E186-98F2-1B1A-E053-4EBD850A0174","beginDate":"2022-03-10","endDate":null,"createdBy":"GALITG","dateCreated":"2022-03-10","modifiedBy":"ONEDATA","dateModified":"2022-03-10","deletedIndicator":"No"},{"value":"None of the above","valueDescription":null,"ValueMeaning":{"publicId":"5913672","version":"1","preferredName":"None of the Above","longName":"5913672","preferredDefinition":"None of the choices above are suitable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None of the Above","conceptCode":"C133298","definition":"None of the choices above are suitable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5499ACEF-10D1-1155-E053-F662850A3955","latestVersionIndicator":"Yes","beginDate":"2017-07-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-07-18","modifiedBy":"KUMMEROA","dateModified":"2022-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3C3B978-FFBD-4BBA-E053-731AD00A5F9D","beginDate":"2022-07-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-14","modifiedBy":"KUMMEROA","dateModified":"2022-07-14","deletedIndicator":"No"},{"value":"Treosulfan","valueDescription":null,"ValueMeaning":{"publicId":"3922372","version":"1","preferredName":"Treosulfan","longName":"3922372","preferredDefinition":"The prodrug of a bifunctional sulfonate alkylating agent with myeloablative, immunosuppressive, and antineoplastic activities. Under physiological conditions, treosulfan converts nonenzymatically to L-diepoxybutane via a monoepoxide intermediate. The monoepoxide intermediate and L-diepoxybutane alkylate DNA at guanine residues and produce DNA interstrand crosslinks, resulting in DNA fragmentation and apoptosis. In escalated doses, this agent also exhibits myeloablative and immunosuppressive activities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Treosulfan","conceptCode":"C1257","definition":"The prodrug of a bifunctional sulfonate alkylating agent with myeloablative, immunosuppressive, and antineoplastic activities. Under physiological conditions, treosulfan converts nonenzymatically to L-diepoxybutane via a monoepoxide intermediate. The monoepoxide intermediate and L-diepoxybutane alkylate DNA at guanine residues and produce DNA interstrand crosslinks, resulting in DNA fragmentation and apoptosis. In escalated doses, this agent also exhibits myeloablative and immunosuppressive activities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8F0C244-B505-23D8-E040-BB89AD430966","latestVersionIndicator":"Yes","beginDate":"2013-10-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-17","modifiedBy":"COOPERM","dateModified":"2020-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F911F5A9-CA82-5A41-E053-731AD00A44E0","beginDate":"2023-04-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-11","deletedIndicator":"No"},{"value":"Total Body Irradiation (TBI) Less Than 800 cGy","valueDescription":null,"ValueMeaning":{"publicId":"13341029","version":"1","preferredName":"Total Body Irradiation (TBI) < 800 cGy","longName":"13341029v1.00","preferredDefinition":"Total Body Irradiation (TBI) < 800 cGy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F911FF23-4EF7-5B56-E053-731AD00A1AA7","latestVersionIndicator":"Yes","beginDate":"2023-04-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-11","modifiedBy":"GDEEN","dateModified":"2023-04-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F911FF23-4EF9-5B56-E053-731AD00A1AA7","beginDate":"2023-04-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-11","deletedIndicator":"No"},{"value":"Total Body Irradiation (TBI) Greater Than or Equal to 800 cGy","valueDescription":null,"ValueMeaning":{"publicId":"13341030","version":"1","preferredName":"Total Body Irradiation (TBI)  800 cGy","longName":"13341030v1.00","preferredDefinition":"Total Body Irradiation (TBI)  800 cGy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F911FF23-4EF8-5B56-E053-731AD00A1AA7","latestVersionIndicator":"Yes","beginDate":"2023-04-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-11","modifiedBy":"GDEEN","dateModified":"2023-04-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F911FF23-4EFA-5B56-E053-731AD00A1AA7","beginDate":"2023-04-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"060A635D-B398-A075-E050-BB89AD434EF6","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-22","modifiedBy":"KUMMEROA","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":"2023.4.11 PVs added per ticket request CADSR0002291. ak 2022.8.24 Released but needs to be cleaned up in the future due to dupe PV 'TBI'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Transplant conditioning regim","type":"Preferred Question Text","description":"Transplant conditioning regimen:","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Planned transplant conditioning regimen agent(s):","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Transplant conditioning regimen agent(s):","url":null,"context":"COG"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"Which treatment(s) was modified?","url":null,"context":"COG"},{"name":"COG CRF TEXT 4","type":"Alternate Question Text","description":"Regimen agent(s):","url":null,"context":"COG"},{"name":"COG CRF Text 5","type":"Alternate Question Text","description":"Name of conditioning agent:","url":null,"context":"COG"},{"name":"COG CRF Text 6","type":"Alternate Question Text","description":"HCT conditioning regimen agent(s):","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"060A635D-B44D-A075-E050-BB89AD434EF6","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"WONGW","dateCreated":"2014-10-22","modifiedBy":"KUMMEROA","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":"2023.4.11 AQT added per ticket request CADSR0002291. ak","unresolvedIssues":null,"deletedIndicator":"No"}}